Skip to main content
. 2014 Nov 21;46(11):e122. doi: 10.1038/emm.2014.72

Figure 3.

Figure 3

Potential targets and inhibitors for (lymph)angiogenic factors in AML. As target molecules involved in lymphangiogenesis, several factors have been applied in clinical studies. AML focused agents typically target dual or multiple protein kinases, and then chemotherapy combined trials with inhibitors to effectively inhibit AML blasts.